The University of Cincinnati's Soma Sengupta, MD, PhD, published an article in the Journal of Neuro-Oncology April 25 discussing her journey and approach to practicing integrative neuro-oncology.

Sengupta, associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist,

A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.

The study, published today in Nature Communications by researchers from King's College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a novel antibody can target and treat melanomas.

Targeting part of an antiviral pathway triggered by the accumulation of a key pathogen shared in Alzheimer's disease and frontotemporal dementia may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.

Multiple sclerosis (MS) is a devastating autoimmune disease that destroys the protective myelin covering around nerves, disrupting communication between the brain and body, and causing patients' ability to move and function to progressively decline. The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 million individuals that currently have to live with the disease. Alarmingly, since 2013, the world-wide prevalence of MS has risen by 30%.

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The novel study uses immunotherapy. It involves taking a patient's own white blood cells, called T-cells, and modifying them so they can identify and target HIV cells to control the virus without medication.

The first participant was dosed with anti-HIV duoCAR T cells at UC Davis Medical Center in mid-August.

Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? In a study led by researchers from Lund University in Sweden, this was investigated by redesigning antibodies and combining them against the virus. The modified antibodies have been tested in human cells and with mice.

Many antibodies used to treat covid infection during the pandemic have been so-called neutralizing antibodies that prevent the virus from infecting the cell.

New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study in Obesity, The Obesity Society's (TOS) flagship journal.

"Access to medicine is a fundamental element of the human right to health. While the obesity pandemic grows, especially amongst low-income communities, effective medical treatments remain inaccessible for millions in need.